Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
about
Targeting MYC Dependence by Metabolic Inhibitors in CancerSpecific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.Rapamycin promotes differentiation increasing βIII-tubulin, NeuN, and NeuroD while suppressing nestin expression in glioblastoma cellsmTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.Translation acrobatics: how cancer cells exploit alternate modes of translational initiation
P2860
Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanistic Target of Rapamyci ...... C mRNAs to Treat Glioblastoma.
@en
type
label
Mechanistic Target of Rapamyci ...... C mRNAs to Treat Glioblastoma.
@en
prefLabel
Mechanistic Target of Rapamyci ...... C mRNAs to Treat Glioblastoma.
@en
P2093
P2860
P356
P1476
Mechanistic Target of Rapamyci ...... C mRNAs to Treat Glioblastoma.
@en
P2093
Alan Lichtenstein
Angelica Benavides-Serrato
Kenna A Landon
Michael E Jung
Tariq Bashir
P2860
P304
14146-14159
P356
10.1074/JBC.M116.726927
P407
P577
2016-05-11T00:00:00Z